TY - JOUR
T1 - Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine
AU - McMurry, Julie A
AU - Gregory, Stephen H
AU - Moise, Leonard
AU - Rivera, Daniel
AU - Buus, Soren
AU - De Groot, Anne S
N1 - Keywords: Adult; Aged; Aged, 80 and over; Antigens, Bacterial; Bacterial Vaccines; Drug Design; Epitopes; Female; Francisella tularensis; Genes, MHC Class II; Humans; Male; Middle Aged; T-Lymphocytes; Tularemia; Vaccination
PY - 2007
Y1 - 2007
N2 - The T lymphocyte antigens, which may have a role in protection against tularemia, were predicted by immunoinformatics analysis of Francisella tularensis Schu4. Twenty-seven class II putative promiscuous epitopes and 125 putative class I supertype epitopes were chosen for synthesis; peptides were tested in vitro for their ability to bind HLA and to induce immune responses from PBMCs of 23 previously infected subjects. While the immune responses of individual subjects showed heterogeneity, 95% of the subjects responded strongly to a pool of 27 promiscuous peptides; 25%, 33%, and 44% of subjects responded to pools of 25 A2, A24, and B7 peptides, respectively. These data can aid in the development of novel epitope-based and subunit tularemia vaccines.
AB - The T lymphocyte antigens, which may have a role in protection against tularemia, were predicted by immunoinformatics analysis of Francisella tularensis Schu4. Twenty-seven class II putative promiscuous epitopes and 125 putative class I supertype epitopes were chosen for synthesis; peptides were tested in vitro for their ability to bind HLA and to induce immune responses from PBMCs of 23 previously infected subjects. While the immune responses of individual subjects showed heterogeneity, 95% of the subjects responded strongly to a pool of 27 promiscuous peptides; 25%, 33%, and 44% of subjects responded to pools of 25 A2, A24, and B7 peptides, respectively. These data can aid in the development of novel epitope-based and subunit tularemia vaccines.
U2 - 10.1016/j.vaccine.2007.01.039
DO - 10.1016/j.vaccine.2007.01.039
M3 - Journal article
C2 - 17291638
SN - 0264-410X
VL - 25
SP - 3179
EP - 3191
JO - Vaccine
JF - Vaccine
IS - 16
ER -